No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
PCRX Pacira BioSciences
- 21.660
- -1.080-4.75%
Close Jul 3 13:00 ET
- 21.780
- +0.120+0.55%
Post 16:54 ET
1.01BMarket Cap14.34P/E (TTM)
22.568High21.405Low1.04MVolume21.710Open22.740Pre Close22.94MTurnover2.27%Turnover Ratio24.34P/E (Static)46.55MShares40.16052wk High1.13P/B997.60MFloat Cap20.52052wk Low--Dividend TTM46.06MShs Float121.950Historical High--Div YieldTTM5.11%Amplitude6.160Historical Low21.966Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
Comments
Recent insider share sale and lack of insider buying in the past year may concern investors. Despite some alignment between management and smaller shareholders, caution is advised due to recent insider selling activity.
Pacira BioSciences Independent Director Gary Pace Sells 85% Of Holding 1
Pacira BioSciences' moderate net income growth is seen as a positive despite a low ROE. The growth could be due to good management decisions or a low payout ratio, as it doesn't pay dividends. Analysts predict future earnings momentum.
1
Multiple insiders selling shares over the past year could be a red flag. However, insider ownership level shows alignment between management and smaller shareholders. Lack of insider purchases in the past year calls for caution.
The market seems to tolerate EPS decline but last year's worse-than-average performance may indicate long term investor concerns.
$Pacira BioSciences(PCRX.US$ $Flexion Therapeutics Inc(FLXN.US$ On October 12, Pacira BioSciences announced that it has entered into a definitive agreement to acquire Flexion Therapeutics For $8.50 per share, or approximately $430 million, in cash to enhance its non-opioid pain portfolio. The deal also includes contingent valuable rights worth up to $8.00 per share, which are tied to Zilretta sales targets and FDA approvals for FX201 and FX301.
3
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg